Viking Therapeutics, Inc. (VKTX) Stock Forecast
VKTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.57 / 5 from 21 analysts
- Price target
- $94.50 average of analyst targets
- Upside to target
- +275.4% from the latest close
- Next earnings
- October 28, 2026 EPS estimate $1.00
- 52-week range
- $25.17 – $42.13
VKTX analyst ratings
21 analystsNumber of analysts at each rating.
VKTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VKTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.06 | −$1.38 | −$0.66 | −$0.81 | −31.0% | 17 |
| Current fiscal year (2026) | −$4.59 | −$5.35 | −$3.81 | −$3.19 | −43.9% | 17 |
| Next fiscal year (2027) | −$4.36 | −$6.04 | −$2.23 | −$4.59 | +5.1% | 17 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VKTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 17 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 17 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 17 |
VKTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VKTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.10 | −$1.07 | −$1.07 | −$1.06 | −$1.06 | −3.5% | 9 up · 6 down |
| Current fiscal year (2026) | −$4.72 | −$4.61 | −$4.61 | −$4.60 | −$4.59 | −2.8% | 9 up · 7 down |
| Next fiscal year (2027) | −$4.57 | −$4.32 | −$4.32 | −$4.40 | −$4.36 | −4.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VKTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VKTX beat in 5 of 12.
What analysts expect from VKTX
21 analysts cover Viking Therapeutics; their consensus rating is strong buy (4.57 on a 1–5 scale, where 5 is a strong buy). The average price target is $94.50, 275.4% above the latest close of $25.17. Analysts expect earnings of −$4.59 per share for 2026, −43.9% from a year earlier. For 2027 the average estimate is −$4.36 per share. Viking Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: VKTX income statement, VKTX key metrics, VKTX chart. See the VKTX stock overview for the latest quote and news.
VKTX forecast FAQ
What is Viking Therapeutics's price target?
The average analyst price target for Viking Therapeutics is $94.50, 275.4% above the latest close of $25.17.
Is Viking Therapeutics a buy, hold or sell?
Of 21 analysts covering Viking Therapeutics, 14 rate it a strong buy, 5 a buy, 2 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Viking Therapeutics's EPS forecast?
Analysts forecast −$4.59 per share for 2026 (range −$5.35 to −$3.81); for 2027 the estimate is −$4.36.
When does Viking Therapeutics report earnings?
Viking Therapeutics is expected to report results for the quarter ending September 30, 2026 on October 28, 2026 after the market closes; the EPS estimate is $1.00.
Does Viking Therapeutics usually beat earnings estimates?
Viking Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.